Process development and cGMP manufacturing of a recombinant ricin vaccine: an effective and stable recombinant ricin A-chain vaccine-RVEc™.
about
The need for continued development of ricin countermeasures.Characterization of Ricin and R. communis Agglutinin Reference Materials.Comparative Adjuvant Effects of Type II Heat-Labile Enterotoxins in Combination with Two Different Candidate Ricin Toxin Vaccine Antigens.Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.Neutralizing monoclonal antibodies against ricin's enzymatic subunit interfere with protein disulfide isomerase-mediated reduction of ricin holotoxin in vitro.Production and Purification of Recombinant Proteins fromEscherichia coli
P2860
Process development and cGMP manufacturing of a recombinant ricin vaccine: an effective and stable recombinant ricin A-chain vaccine-RVEc™.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Process development and cGMP m ...... t ricin A-chain vaccine-RVEc™.
@en
Process development and cGMP m ...... t ricin A-chain vaccine-RVEc™.
@nl
type
label
Process development and cGMP m ...... t ricin A-chain vaccine-RVEc™.
@en
Process development and cGMP m ...... t ricin A-chain vaccine-RVEc™.
@nl
prefLabel
Process development and cGMP m ...... t ricin A-chain vaccine-RVEc™.
@en
Process development and cGMP m ...... t ricin A-chain vaccine-RVEc™.
@nl
P2093
P2860
P356
P1476
Process development and cGMP m ...... t ricin A-chain vaccine-RVEc™.
@en
P2093
Changhong Lindsey
Javier G Seravalli
Jay C Harner
Kevin Van Cott
Leonard A Smith
Michael M Meagher
Robert Wannemacher
Roger G Ladd
S Todd Swanson
Scott K Johnson
P2860
P304
P356
10.1002/BTPR.631
P50
P577
2011-05-31T00:00:00Z